Noile-Immune Biotech (TSE:4893) Debt-to-Revenue : 0.00 (As of Mar. 2024)

Noile-Immune Biotech Debt-to-Revenue Chart

Noile-Immune Biotech Quarterly Data
	Dec20	Dec21	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Revenue	Get a 7-Day Free Trial				-	-	-	-	-

Competitive Comparison of Noile-Immune Biotech's Debt-to-Revenue

For the Biotechnology subindustry, Noile-Immune Biotech's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Noile-Immune Biotech's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Noile-Immune Biotech's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Noile-Immune Biotech's Debt-to-Revenue falls into.

Noile-Immune Biotech Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Noile-Immune Biotech's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Noile-Immune Biotech's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Mar. 2024) Revenue data.

Noile-Immune Biotech Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Noile-Immune Biotech's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Noile-Immune Biotech (TSE:4893) Business Description